ÖŞÖmer Faruk Şahin

Ömer Faruk Şahin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ömer Faruk Şahin has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Isolated Primary B-Cell Lymphoma of the Larynx Mimicking Carcinoma: 18F-FDG PET/CT Findings

    by Zehranur Tosunoğlu, Ömer Faruk Şahin

    Primary laryngeal lymphoma is an extremely rare extranodal manifestation of non-Hodgkin lymphoma, accounting for less than 1% of all laryngeal neoplasms. We report a case of isolated primary B-cell lymphoma of the larynx evaluated with 18F-FDG PET/CT imaging. PET/CT demonstrated intense FDG uptake (SUVmax: 16.3) in the laryngeal lesion, while mild FDG uptake (SUVmax: 5.5) was observed in the right palatine tonsil, likely of inflammatory origin. The patient underwent R-CHOP therapy, and both interim and post-treatment PET/CT scans showed complete metabolic and anatomic response. This case highlights the critical role of 18F-FDG PET/CT in the staging and management of rare primary laryngeal lymphomas.

  • Clinical Value of 68Ga-DOTA-Bombesin PET/CT Compared With 18F-FDG PET/CT in the Staging of Breast Cancer

    by Mehmet Can Baloglu, Rahime Şahin, Zehranur Tosunoglu, Ahmet Ertugrul Ozturk, Ömer Faruk Şahin, Ediz Beyhan, Özge Erol Fenercioglu, Göksel Alcin, Nurhan Ergul, Tevfik Fikret Cermik, et al.

    Aim: To prospectively evaluate the diagnostic performance of 68 Ga-DOTA-Bombesin PET/CT compared with 18 F-FDG PET/CT in breast cancer (BC), emphasizing its utility across molecular subtypes and nodal staging. Patients and Methods: Twenty-four patients with biopsy-proven BC who underwent both 68 Ga-DOTA-Bombesin and 18 F-FDG PET/CT were included. Imaging findings were analyzed on a per-lesion and per-patient basis for primary tumor detection, axillary lymph-node involvement, and distant metastases. Quantitative parameters (SUVmax, MTV, and tumor-to-background ratios) were compared across histopathologic and receptor subgroups, with histopathology as the reference standard. Results: 68 Ga-DOTA-Bombesin visualized 92.3% of primary tumors, achieving comparable sensitivity to 18 F-FDG (84.6%) but higher specificity in nodal staging (100% vs. 53.8%). Bombesin uptake correlated strongly with estrogen receptor positivity and a lower Ki-67 index ( P 68 Ga-DOTA-Bombesin PET/CT provides a receptor-specific imaging approach in BC, showing complementary strengths to 18 F-FDG, particularly in hormone-receptor–positive and low-proliferation tumors. Its superior nodal specificity and theranostic potential support further evaluation of GRPR-targeted imaging and therapy in personalized BC management.

  • The Sunburst Sign in the Mesentery: Unveiling the Diagnosis With ⁶⁸Ga DOTATATE PET/CT

    by Ömer F. Şahin, Dilruba Şahin, Zehranur Tosunoğlu

    Contrast-enhanced abdominal CT of a 57-year-old man presenting with abdominal pain and diarrhea revealed a spiculated, calcified mesenteric mass, initially suggesting a desmoid tumor (DT). The lesion’s ametabolic nature on 18 F-FDG PET/CT supported this suspicion. However, ⁶⁸Ga DOTATATE PET/CT demonstrated intense uptake in both the mesenteric mass, which exhibited a “sunburst” calcification pattern, and the primary ileal focus. Histopathology confirmed an ileal neuroendocrine tumor (NET) with mesenteric lymph node metastasis. This case highlights the critical role of ⁶⁸Ga DOTATATE PET/CT in the differential diagnosis, primary site detection, and accurate staging of FDG-negative mesenteric masses associated with a desmoplastic reaction.

  • Diagnostic Performance of 68Ga DOTA-Pentixafor PET/CT in Benign Functional Adrenal Cortical Lesions

    by Ömer F. Şahin, Zehranur Tosunoğlu, Rahime Şahin, Dilruba Şahin, Göksel Alçin, Esra Arslan, Tevfik F. Çermik

    Objective: This prospective study evaluated the diagnostic performance of 68 Ga DOTA-Pentixafor PET/CT in characterizing the functional properties and lateralization of aldosterone-producing and cortisol-producing adrenal cortical lesions. The contribution of Pentixafor PET/CT to diagnosis and treatment planning was assessed in comparison with CT, MRI, and 18 F-FDG PET/CT. Patients and Methods: Twenty-five patients with suspected benign functional adrenal cortical masses were included. All patients underwent whole-body imaging at 1 hour and delayed abdominal imaging at 2 hours following intravenous administration of 18 F-FDG and 68 Ga DOTA-Pentixafor. Lesion SUVmax, LCRSUVmax, and LLRSUVmax values were analyzed and correlated with laboratory parameters, other imaging modalities, and postoperative clinical and pathologic outcomes. Results: 68 Ga DOTA-Pentixafor PET/CT demonstrated distinct focal uptake relative to the contralateral adrenal gland and liver parenchyma in 6/6 (100%) patients with suspected PA, 5/18 (27.7%) with suspected CS, and 1/1 (100%) with suspected EAS. Among patients with focal uptake who underwent surgery, all PA (5/5) and all CS (5/5) cases were confirmed as adrenocortical adenomas, resulting in no false-positive findings (PPV 100%). However, due to 2 false-negative CS cases, pentixafor PET/CT demonstrated an overall sensitivity of 83.3%, specificity of 100%, and accuracy of 85.7%. Thresholds of SUVmax >15.11, LCRSUVmax >1.74, and LLRSUVmax >4.36 yielded sensitivities of 33.3%, 41.7%, and 41.7%, respectively, while maintaining 100% specificity. Clinical and biochemical improvement was observed in 100% (5/5) of operated PA patients and 100% (5/5) of operated CS patients. Follow-up of nonoperated patients is ongoing. Conclusion: 68 Ga DOTA-Pentixafor PET/CT is a valuable diagnostic and potentially therapeutic tool for benign functional adrenal cortical disorders such as PA, CS, and EAS, with the potential to establish a new standard in minimally invasive patient management.


  • Physiological differences in bone uptake of [99mTc]Tc-pyrophosphate in men and women undergoing cardiac scintigraphy

    by Elife Akgün, Göksel Alçın, Ömer Faruk Şahin, Dilruba Şahin, Mustafa Enes Kaya, Selin Gül Yaran, Cihan Şin, Özge Vural Topuz, Burcu Esen Akkaş, Meryem Kaya, et al.


  • Open Access

    Cutaneous Metastase of Rectal Neuroendocrine Carcinoma Revealed on 18F-FDG PET/CT

    by Ömer Faruk Şahin, Rahime Şahin, Mehmet Can Baloğlu, Tevfik Fikret Çermik, Nurhan Ergül

    Rectal neuroendocrine carcinomas constitute 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography for restaging after 6 cycles of chemotherapy and radiotherapy. Intensely increased 18F-FDG uptake in the right cutaneous inguinal region was consistent with neuroendocrine carcinoma metastasis with biopsy from the same region.

  • Open Access

    Testicular Metastasis of Jejunal Neuroendocrine Tumor on 68Ga-DOTATATE PET/CT

    by Ömer Faruk Şahin, Özge Erol Fenercioğlu, Ediz Beyhan, Tevfik Fikret Çermik, Nurhan Ergül

    Neuroendocrine tumors are slow-growing tumors originating from neuroendocrine cells and capable of metastasis. Most of them are found in the gastrointestinal tract; however, they can also be rarely seen in other organs. Testicular neuroendocrine tumors account for less than 1% of all testicular neoplasms. They may present as primary testicular or secondary tumors from extratesticular sources. Jejunal neuroendocrine tumor metastasis to the testis is extremely rare. We present the case of a 61-year-old man with a jejunal neuroendocrine tumor and metastases to bilateral testicles revealed on Gallium-68-DOTATATE positron emission tomography/computed tomography.


  • Open Access

    Prognostic Significance of 18F-FDG PET/CT Imaging in Survival Outcomes in Patients with Renal Cell Carcinoma

    by Gamze Tatar, Cihan Gündoğan, Ömer Faruk Şahin, Esra Arslan, Nurhan Ergül, Tevfik Fikret Çermik

    Renal cell carcinoma (RCC) comprises 85%-90% of primary renal malignant tumors originating from the renal tubular epithelium and has different genetic characteristics. This study aimed to investigate the potential predictive role of 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) and metabolic parameters in overall survival (OS) analysis in patients with RCC. 18F-FDG PET/CT images of 100 patients performed for initial staging before surgical or oncological treatments were analyzed retrospectively. Maximum standard uptake value (SUVmax-T) of the primary tumor was calculated and its relationship to patient survival was analyzed. The median follow-up time was 5.61 years (0.01-8.7 years). SUVmax-T levels in the patients ranged from 2.1 to 48.9 (median 5.9, mean 9.0±7.9). SUVmax-T was significantly higher in RCC-related death more positive than in the negative cases (pmax-T for estimating OS was a cut-off level of 5.4, which maintained sensitivity and specificity of 81% and 75%, respectively. However, cancer staging remained independent significance for OS (pmax of primary tumor and cancer stage were demonstrated as significant prognostic factors for OS in patients with RCC. Evaluation of 18F-FDG accumulation with PET/CT may help plan treatment strategies and predict survival outcomes of these patients at diagnosis.